Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054165 | 1.00 | KIF11 (0.38) | KIF11MGAT2EPHX2ELANECYP3A4 | |
| SCHEMBL8195595 | 1.00 | KIF11 (0.38) | KIF11MGAT2EPHX2ELANECYP3A4 | |
| SCHEMBL7576035 | 0.88 | BACE1 (0.36) | MGAT2ELANEGRIN2B | |
| SCHEMBL7544880 | 0.88 | BACE1 (0.36) | MGAT2ELANEGRIN2B | |
| SCHEMBL7589834 | 0.87 | KIF11 (0.38) | KIF11MGAT2EPHX2CYP3A4HTT | |
| SCHEMBL7576610 | 0.86 | FASN (0.34) | — | |
| SCHEMBL7551254 | 0.86 | FASN (0.34) | — | |
| SCHEMBL7601012 | 0.86 | CYP19A1 (0.36) | — | |
| SCHEMBL7581539 | 0.86 | TP53 (0.34) | HTT | |
| SCHEMBL13054757 | 0.86 | TP53 (0.34) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | KIF11 3749/4885MGAT2 1683/4885EPHX2 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.